Beigene (BGNE) Downgraded by ValuEngine to Sell

ValuEngine lowered shares of Beigene (NASDAQ:BGNE) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

Other analysts have also issued research reports about the company. Maxim Group set a $120.00 target price on Beigene and gave the company a buy rating in a report on Monday, December 18th. Robert W. Baird restated a neutral rating and issued a $83.00 target price (up previously from $58.00) on shares of Beigene in a report on Tuesday, November 14th. Cowen restated a buy rating on shares of Beigene in a report on Tuesday, November 14th. Morgan Stanley restated an overweight rating and issued a $95.00 target price (up previously from $87.00) on shares of Beigene in a report on Friday, October 6th. Finally, Zacks Investment Research lowered Beigene from a hold rating to a sell rating in a report on Monday, November 13th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Beigene presently has an average rating of Hold and a consensus price target of $96.67.

Beigene (NASDAQ BGNE) traded down $1.98 on Wednesday, hitting $100.39. The stock had a trading volume of 80,200 shares, compared to its average volume of 156,233. The stock has a market capitalization of $4,630.00 and a price-to-earnings ratio of -76.63. Beigene has a one year low of $30.02 and a one year high of $118.95. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.33 and a quick ratio of 9.27.

Beigene (NASDAQ:BGNE) last released its earnings results on Monday, November 13th. The company reported $2.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.23 by $2.31. The business had revenue of $220.21 million during the quarter, compared to analysts’ expectations of $1.55 million. During the same quarter in the previous year, the company earned ($1.08) EPS. equities analysts expect that Beigene will post -2.04 earnings per share for the current year.

In other news, CMO Amy C. Peterson sold 3,601 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $82.96, for a total value of $298,738.96. Following the transaction, the chief marketing officer now directly owns 1,201 shares of the company’s stock, valued at $99,634.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John Oyler sold 20,137 shares of the company’s stock in a transaction on Tuesday, December 26th. The stock was sold at an average price of $96.46, for a total transaction of $1,942,415.02. Following the completion of the transaction, the chief executive officer now directly owns 110,179 shares in the company, valued at $10,627,866.34. The disclosure for this sale can be found here. Insiders sold 483,482 shares of company stock worth $42,139,474 over the last ninety days. 19.90% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP acquired a new position in shares of Beigene in the third quarter worth $160,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Beigene in the third quarter worth $248,000. SG Americas Securities LLC acquired a new position in Beigene during the second quarter worth $111,000. Aperio Group LLC acquired a new position in Beigene during the third quarter worth $301,000. Finally, Jane Street Group LLC acquired a new position in Beigene during the third quarter worth $339,000. 55.32% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://transcriptdaily.com/2018/01/05/beigene-bgne-downgraded-by-valuengine-to-sell.html.

Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply